Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 10/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | MITF | O75030 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | PPP1CA | P62136 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822086 | 0.90 | TRPM8 (0.62) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL4475741 | 0.88 | TRPM8 (0.67) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2820381 | 0.88 | TRPM8 (0.61) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2821539 | 0.88 | TRPM8 (0.60) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2820216 | 0.88 | TRPM8 (0.60) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2821547 | 0.88 | TRPM8 (0.60) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| Hydrochloric Acid SCHEMBL2821559 | 0.87 | TRPM8 (0.59) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2821677 | 0.87 | TRPM8 (0.59) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2821153 | 0.85 | TRPM8 (0.57) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL23837648 | 0.85 | TRPM8 (0.73) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742634-B1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-10-27 | — | — | EP | claimed |
| US-7560464-B2 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2009-07-14 | — | — | US | claimed |
| EP-1742634-B1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-7560464-B2 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1742634-A1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAgen, Incorporated (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005099711-A1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | KCNJ2, KCNJ1, KCNJ11 | TRPM8 61/4885L3MBTL1 4011/4885SMN1; SMN2 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.